Aktis Oncology, Inc. (AKTS) stock intrinsic value fair value estimate & owner earnings analysis

Aktis Oncology is a Boston clinical-stage biotech building cancer drugs that deliver the alpha-emitting isotope actinium-225 to tumors using small engineered 'miniproteins'. Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4 (the same target as Pfizer's Padcev) in bladder (urothelial) cancer and other Nectin-4 tumors and is in a US Phase 1b trial, with first dose-escalation results expected around early 2027. A second candidate, AKY-2519 against B7-H3, was cleared by the FDA for a Phase 1b trial planned for mid-2026. Separately, a May 2024 discovery deal with Eli Lilly paid $60 million upfront and offers up to $1.2 billion of milestones plus royalties on targets outside Aktis's own pipeline; Aktis does the discovery work and Lilly runs development. No product has been approved or sold. Earnings. The business has never produced owner earnings. Measured as operating cash flow, stripped of working-capital swings (including the one-time $58.5 million of Lilly prepayment booked in 2024), less stock compensation and upkeep capital spending, the business consumed about $47 million in 2024 and $67 million in 2025, and about $50 million in the first half of 2026 alone as trials ramped. Revenue is collaboration income from Lilly ($6.5 million in 2025, $6.6 million in the first half of 2026) and comes from recognizing the upfront payment already received, not new cash. There is no earnings level to capitalize, so the shares are valued on the cash the company holds, what it is committed to spend, and what can actually be evidenced about the pipeline. Balance sheet. At June 30, 2026 the company held $517 million of cash and marketable securities (after $335 million of net IPO proceeds in January 2026) and has no borrowings. Total liabilities of $73 million are mostly deferred revenue that will be worked off through the Lilly research program and ordinary payables, which are already reflected in the cash burn. About 53.4 million shares are outstanding, roughly 55 million on a diluted basis including in-the-money options. Management says the cash funds operations into 2029. What we credit and what we do not. None of the drug candidates has human efficacy data, and the only revenue-generating contract (Lilly) pays milestones only on events that have not happened. Under our approach, that pipeline value is not in the bag, so no case assigns value to future drug sales; the cases differ in how much of the cash is spent before the outcome is known and what is left for owners. Bear case (about $3 per share). The Phase 1b data for AKY-1189 disappoint and AKY-2519 adds nothing. The company spends to its stated runway, roughly $280-320 million over the next two-and-a-half to three years at the current and rising burn, before narrowing or winding down. That is the common path for early radiopharmaceutical and oncology platforms whose lead fails. What remains, roughly $200 million, less wind-down and lease costs and discounted for the wait, is worth about $3 a share. Business value is negative (it consumes cash); the company owes no debt; the residual is cash. Base case (about $6.50 per share). The company spends through its first meaningful clinical readouts (early 2027 for AKY-1189, later for AKY-2519), consuming roughly $170-200 million, and continues the Lilly research program with its costs reimbursed above the cap. With no evidenced commercial value yet, owners are left with about $320-350 million of cash, about $6.50 a share after discounting, plus an option on the pipeline that we do not price. Bull case (about $11 per share). The company's own levers work: early data are good enough that a partner funds much of the later development (as Lilly already does for the platform), so most of today's cash is preserved, and Lilly pays early research and development milestones from the contracted $525 million pool as its selected targets reach human imaging studies. That leaves roughly the full $9.40 a share of cash plus about a dollar of near-term milestones. What would make this wrong. On the upside, a clean Phase 1b readout in an established target like Nectin-4 could create value well beyond cash, which none of our cases credits. On the downside, actinium-225 supply is scarce and the product has a short shelf life, so manufacturing or supply problems could delay data and burn cash faster; and the company could raise more equity at low prices, diluting owners. The previous analysis anchored part of its values to the share price, so its figures are not comparable with these; the business itself has not changed materially since then beyond about $50 million of additional cash spent in the first half of 2026. Margin-of-safety price. We are fairly certain about the cash and almost certain the company will keep spending it; we cannot know the clinical outcome. The worst plausible outcome is that the lead program fails and management keeps spending on the remaining programs rather than returning cash, leaving owners perhaps $2-3 a share years from now. There is no debt and no customer concentration that could force a bad outcome, so the structure survives a failure; the risk is waste, not insolvency. The business pays nothing in the meantime, and the decisive event, the first AKY-1189 data, is roughly a year or more away. The margin-of-safety price of $3.50 values the company at about $190 million while it holds over $500 million in cash: if most of the cash is spent and the pipeline proves worthless, the bear case implies a modest loss from that price, while a reasonable data readout or a partnering deal, or simply a decision to stop spending, would bring the value per share into the $6-10 range within an assumed two-to-three-year holding period, which the base and bull cases imply is more than a 20% yearly return. At prices much above that, any return depends on the clinical result, which we cannot judge.